Cargando…
Bevacizumab specifically decreases elevated levels of circulating KIT(+)CD11b(+) cells and IL-10 in metastatic breast cancer patients
BACKGROUND: Whether bevacizumab exerts its anti-tumor properties through systemic effects beyond local inhibition of angiogenesis and how these effects can be monitored in patients, remain largely elusive. To address these questions, we investigated bone marrow-derived cells and cytokines in the per...
Autores principales: | Cattin, Sarah, Fellay, Benoît, Pradervand, Sylvain, Trojan, Andreas, Ruhstaller, Thomas, Rüegg, Curzio, Fürstenberger, Gregor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905463/ https://www.ncbi.nlm.nih.gov/pubmed/26840567 http://dx.doi.org/10.18632/oncotarget.7097 |
Ejemplares similares
-
Circulating immune cell populations related to primary breast cancer, surgical removal, and radiotherapy revealed by flow cytometry analysis
por: Cattin, Sarah, et al.
Publicado: (2021) -
Characterization and In Vivo Validation of a Three-Dimensional Multi-Cellular Culture Model to Study Heterotypic Interactions in Colorectal Cancer Cell Growth, Invasion and Metastasis
por: Cattin, Sarah, et al.
Publicado: (2018) -
MAGI1 Prevents Senescence and Promotes the DNA Damage Response in ER(+) Breast Cancer
por: Wörthmüller, Janine, et al.
Publicado: (2023) -
Emodin Inhibits Inflammation, Carcinogenesis, and Cancer Progression in the AOM/DSS Model of Colitis-Associated Intestinal Tumorigenesis
por: Zhang, Yunsha, et al.
Publicado: (2021) -
CERN's FMC Kit
por: Van der Bij, E, et al.
Publicado: (2014)